Literature DB >> 3931954

Oxidation of hydrazine metabolites formed from isoniazid.

B H Lauterburg, C V Smith, E L Todd, J R Mitchell.   

Abstract

Studies in rats indicate that the metabolic activation of acetylhydrazine, a metabolite of isoniazid, is a critical determinant of the hepatotoxicity of isoniazid. As demonstrated in that model, the formation of 14CO2 after the administration of 14C-acetylisoniazid reflects the activity of the toxic pathway. A similar approach in man should make it possible to demonstrate the presence and to assess the quantitative importance of this toxifying pathway, and thus to evaluate its role in the pathogenesis of isoniazid hepatitis. We gave 300 mg isoniazid together with 10 microCi 14C-acetylisoniazid (12 mg) to 17 healthy subjects and determined the time course of the plasma concentrations of isoniazid, acetylisoniazid, acetylhydrazine, and diacetylhydrazine and of the exhalation of 14CO2. The time course of 14CO2 in breath closely paralleled the plasma concentration-time curve of acetylhydrazine but not those of acetylisoniazid or diacetylhydrazine, indicating that the 14CO2 originated directly from the metabolism of acetylhydrazine. The cumulative exhalation of 14CO2 increased with decreasing rate of acetylation of isoniazid, such that slow acetylators generated more 14CO2 than rapid acetylators. Simulation studies demonstrated that even if the data are corrected for the different formation of acetylisoniazid from isoniazid in slow and rapid acetylators, the slow acetylators still generated more 14CO2. The data therefore indicate that a substantial fraction of the acetylhydrazine formed from isoniazid passes through a pathway that has been shown in animals to generate highly reactive and hepatotoxic intermediates.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931954     DOI: 10.1038/clpt.1985.225

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis.

Authors:  Christopher Trent Brewer; Lei Yang; Anne Edwards; Yan Lu; Jonathan Low; Jing Wu; Richard E Lee; Taosheng Chen
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

2.  Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.

Authors:  E Peretti; G Karlaganis; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Isoniazid protects mice against endotoxin lethality without influencing tumor necrosis factor synthesis and release.

Authors:  R Urbaschek; D N Männel; R Urbanczik
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

4.  NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

Authors:  Norihide Higuchi; Naoko Tahara; Katsunori Yanagihara; Kiyoyasu Fukushima; Naofumi Suyama; Yuichi Inoue; Yoshitsugu Miyazaki; Tsutomu Kobayashi; Kohichiro Yoshiura; Norio Niikawa; Chun-Yang Wen; Hajime Isomoto; Saburou Shikuwa; Katsuhisa Omagari; Yohei Mizuta; Shigeru Kohno; Kazuhiro Tsukamoto
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

Review 5.  Mechanism of isoniazid-induced hepatotoxicity: then and now.

Authors:  Imir Metushi; Jack Uetrecht; Elizabeth Phillips
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

6.  Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients.

Authors:  W L Gent; H I Seifart; D P Parkin; P R Donald; J H Lamprecht
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 7.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

8.  A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.

Authors:  Henrik Cordes; Christoph Thiel; Hélène E Aschmann; Vanessa Baier; Lars M Blank; Lars Kuepfer
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

9.  Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India.

Authors:  Faisal Imam; Manju Sharma; Khalid Umer Khayyam; Mohammad Rashid Khan; Mohammad Daud Ali; Wajhul Qamar
Journal:  Saudi Pharm J       Date:  2020-04-19       Impact factor: 4.330

10.  Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.

Authors:  Bing Chen; Hao-Qiang Shi; Meihua Rose Feng; Xi-Han Wang; Xiao-Mei Cao; Wei-Min Cai
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.